Raymond Dwek Sells 3,000 Shares of United Therapeutics Co. (NASDAQ:UTHR) Stock

United Therapeutics Co. (NASDAQ:UTHR) Director Raymond Dwek sold 3,000 shares of the firm’s stock in a transaction on Monday, April 14th. The shares were sold at an average price of $285.16, for a total value of $855,480.00. Following the completion of the transaction, the director now owns 1,750 shares of the company’s stock, valued at approximately $499,030. This represents a 63.16 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Raymond Dwek also recently made the following trade(s):

• On Monday, April 7th, Raymond Dwek sold 4,000 shares of United Therapeutics stock. The shares were sold at an average price of $284.55, for a total transaction of $1,138,200.00.

United Therapeutics Price Performance

NASDAQ:UTHR opened at $285.19 on Thursday. The stock has a market cap of $12.81 billion, a P/E ratio of 12.52, a PEG ratio of 0.97 and a beta of 0.63. United Therapeutics Co. has a 1-year low of $232.84 and a 1-year high of $417.82. The firm has a 50-day moving average of $319.20 and a two-hundred day moving average of $349.67.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The company had revenue of $735.90 million during the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same quarter last year, the firm earned $4.36 EPS. As a group, equities analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. StockNews.com lowered shares of United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and issued a $425.00 price target on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group increased their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, two have given a hold rating and ten have issued a buy rating to the company. Based on data from MarketBeat, United Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $388.25.

Institutional Trading of United Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. Newbridge Financial Services Group Inc. acquired a new position in shares of United Therapeutics in the 4th quarter valued at $25,000. Dunhill Financial LLC increased its stake in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 50 shares during the last quarter. State of Wyoming bought a new position in United Therapeutics during the fourth quarter valued at about $62,000. Millstone Evans Group LLC bought a new position in shares of United Therapeutics in the 4th quarter valued at approximately $67,000. Finally, Curat Global LLC bought a new stake in shares of United Therapeutics during the 1st quarter worth $63,000. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.